Tag: neuromodulation

Reading of the Week: AI Chatbots for Mental Healthcare – the New NEJM AI Paper; Also, Neuromodulation for Schizophrenia (AJP)

April 10, 2025 /

From the Editor

Thought logs. Homework. Exposure. Psychotherapy is evidenced for the treatment of many mental disorders – but access is problematic. Can technology help? Is AI a game changer?

In a new NEJM AI paper, Dr. Michael V. Heinz (of Dartmouth College) and his co-authors attempt to answer these questions. In an RCT, they compared 210 participants receiving a chatbot intervention (Therabot) with a control group, analyzing symptoms of mood, anxiety, and disordered eating. “As the first RCT of its kind, our study supports the feasibility, acceptability, and effectiveness of a fine-tuned, fully GenAI–powered chatbot for treating mental health symptoms.” We consider the paper and its implications, and tap the expertise of Dr. John Torous (of Harvard University).

An AI bot for better mental health?

In this week’s other selection, we look at a new review from The American Journal of Psychiatry. Drs. Nicholas H. Neufeld and Daniel M. Blumberger (both of the University of Toronto) provide an update on neuromodulation strategies for schizophrenia, drawing on nearly 140 citations and reviewing different technologies “that span electrical, magnetic, and ultrasound forms of stimulation.” They note: “The evolution of interventions holds the promise of fewer adverse effects and a noninvasive approach, increasing the scale at which these interventions may be offered in hospital and community settings.”

DG

Continue reading

Reading of the Week: Antidepressants & Discontinuation Symptoms – the New Lancet Psych Study; Also, Neuromodulation and Digital Health Technology

June 27, 2024 /

From the Editor

“Once I start taking them, I’m stuck.” When discussing the possible initiation of an antidepressant trial, a patient recently expressed his fear: that he wouldn’t be able to stop the medication because of discontinuation symptoms. These symptoms are debated. Some claim they are very common – though that’s not widely reported in the literature. 

How frequently do these symptoms occur? What percentage of patients experience severe symptoms? Are some antidepressants more associated with this problem than others? Dr. Jonathan Henssler (of the University of Cologne) and his co-authors attempt to answer these questions with an impressive, new systematic review and meta-analysis, published in Lancet Psychiatry. They drew on 79 studies involving more than 21 000 people. “The incidence of antidepressant discontinuation symptoms is approximately 15%, affecting one in six to seven patients who discontinue their medication.” We consider the paper and its clinical implications.

Will the stigma around ECT fade? Will ECT eventually be replaced by ketamine and MST? What’s the future of neuromodulation? We answer these questions and more in the second selection, the latest Quick Takes podcast interview. Dr. Daniel Blumberger, scientific director of CAMH’s Temerty Centre for Therapeutic Brain Intervention and professor at the University of Toronto, notes that ECT still has a unique place. “As far as medical treatments go, ECT is the safest medical procedure in all of medicine.”

And in the third selection, Dr. John Torous (of the Harvard University) and his co-authors focus on digital mental health in a new Viewpoint published in JAMA Psychiatry. They argue that we tend to both overstate and underappreciate the risks and benefits of digital mental health interventions. “Patients and clinicians should not assume wellness digital health technologies are always dangerous, nor should they assume health technologies are always safe.”

DG

Continue reading